Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Ampli Biomedical Consulting AB
AB
Active
Org 5593384661
Norra Vallgatan 2 B, 223 62
Lund
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2021
0 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Ampli Biomedical Consulting AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
0M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
0M
2024
Income statement
SEK thousands
Item
2022
2023
2024
Revenue
34
65
136
Staff expenses
—
−25
−5
EBITDA
−5
12
12
Depreciation & amort.
—
—
—
EBIT
−5
12
12
Net financials
—
—
−0
Profit before tax
−5
12
12
Tax
—
−7
−5
Net profit
−5
5
7
Balance sheet
SEK thousands
Item
2022
2023
2024
Total assets
31
66
79
Equity
20
25
32
Long-term debt
—
—
—
Short-term debt
12
17
22
Total debt
12
17
22
Financial ratios
5-year trend
EBITDA margin
8.9%
This company
15.8%
Market median
-44% vs market
2022
2024
Equity ratio
40.7%
This company
38.2%
Market median
+7% vs market
2022
2024
Return on equity
23.1%
This company
18.4%
Market median
+26% vs market
2022
2024
Net profit margin
5.5%
This company
8.1%
Market median
-32% vs market
2022
2024
Asset turnover
1.71×
This company
1.12×
Market median
+53% vs market
2022
2024
Debt / equity
1.46×
This company
0.62×
Market median
-135% vs market
2022
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-10-04 – 2022-12-31
View
PDF
More on Ampli Biomedical Consulting AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
